Assessment Questions: Diving Deep: The Literature on GLP-1 Agonists

What was the primary focus of the Surmount 1 trial?

A) Evaluating the effectiveness of semaglutide in reducing cardiovascular events
B) Assessing tirzepatide’s impact on weight loss in patients without diabetes
C) Comparing GLP-1 receptor agonists to SGLT2 inhibitors for diabetes control
D) Investigating the role of GLP-1s in preventing Alzheimer’s disease

What was a major limitation of the Surmount 1 trial?

A) It only included patients with type 2 diabetes
B) The study population may have had greater commitment to weight loss than the general population
C) It used a crossover design rather than a placebo comparison
D) The trial lasted only 4 weeks

What type of study design was used in the trial assessing the gastrointestinal side effects of GLP-1 receptor agonists?

What is a key limitation of the gastrointestinal side effects study discussed in the episode?

What was the primary finding of the SELECT trial?

A) Semaglutide reduced cardiovascular events in patients with obesity and no diabetes
B) Tirzepatide improved insulin sensitivity in prediabetic patients
C) GLP-1 receptor agonists were less effective than SGLT2 inhibitors for weight loss
D) Bupropion/naltrexone was superior to GLP-1s for long-term weight management

What was the number needed to treat (NNT) in the SELECT trial?

What is the mechanism of action of Retatrutide, the triple hormone receptor agonist?

What was the average weight loss achieved in the phase 2 trial of Retatrutide?

What percentage of patients with prediabetes in the Retatrutide phase 2 trial returned to normal glycemic levels?

What was a key reason the SELECT trial did not apply to all patients with obesity?